Last edition
News about "COYA 302"
Coya Therapeutics Wins FDA Fast Track for COYA 302 in Amyotrophic Lateral Sclerosis
Coya Therapeutics receives US Food and Drug Administration (FDA) Fast Track designation for COYA 302, an investigational biologic therapy for Amyotrophic Lateral Sclerosis (ALS).
COYA 302 | 13/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members